Intravenous or subcutaenous rituximab for FL in the SABRINA study

Share :
Published: 4 Dec 2016
Views: 2057
Dr Andrew Davies - University of Southampton, Southampton, UK

Dr Davies speaks with ecancertv at ASH 2016 about the efficacy of treating follicular lymphoma with a fixed subcutaneous dose.

He describes the safety profile of both treatment regimens, with non-inferiority being determined for subcutaneous delivery, though a significant benefit in cost, time and resource demand.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.